{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:03:50Z","timestamp":1782727430958,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Posterior reversible encephalopathy syndrome (PRES) is characterized by headaches, vision loss, confusion, encephalopathy, seizures, and reversible focal edema on neuroimaging. Early recognition and treatment of PRES are essential to prevent severe complications. Lenvatinib is a multi-targeted kinase inhibitor that is used as a first-line treatment for patients with hepatocellular carcinoma (HCC). Lenvatinib-induced PRES is a less commonly recognized side effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 72-year-old female patient with HCC, who had no history of hypertension, received lenvatinib therapy. The patient exhibited symptoms such as confusion, altered mental status, headaches, and severe hypertension during treatment. Neuroimaging revealed characteristic findings of vasogenic edema in the white matter of the brain. The patient\u2019s neurological symptoms gradually improved after lenvatinib discontinuation, and follow-up imaging showed a reduction in the white matter abnormalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The underlying mechanisms of PRES induced by lenvatinib remain unclear, but hypertension is considered a crucial factor in its pathogenesis. This case report adds to the understanding of the potential adverse effects associated with lenvatinib in patients with HCC, emphasizing the need for vigilance in monitoring and managing such complications to ensure the safety and wellbeing of patients undergoing this treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1487009","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T13:42:14Z","timestamp":1742564534000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Posterior reversible encephalopathy syndrome after lenvatinib treatment for hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Minchun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingze","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangkang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1605","DOI":"10.1002\/cnr2.1605","article-title":"Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer-A case report","volume":"5","author":"Abhishek","year":"2022","journal-title":"Cancer Rep. Hob."},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ijms18030625","article-title":"The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors","volume":"18","author":"Ancker","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00415-022-11450-y","article-title":"Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study","volume":"270","author":"Balcerac","year":"2023","journal-title":"J. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s11011-015-9746-1","article-title":"Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited","volume":"31","author":"Butterworth","year":"2016","journal-title":"Metab. Brain Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10637-017-0521-5","article-title":"Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature","volume":"36","author":"Deguchi","year":"2018","journal-title":"Invest New Drugs"},{"key":"B6","unstructured":"FDALabel-LENVIMA(Lenvatinib mesylate capsules)(eisailnc)\n          \n          \n          2021"},{"key":"B7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5811\/cpcem.2017.1.30607","article-title":"Posterior reversible encephalopathy syndrome presenting as stroke mimic","volume":"1","author":"Frick","year":"2017","journal-title":"Clin. Pract. Cases Emerg. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMra2114482","article-title":"Posterior reversible encephalopathy syndrome","volume":"388","author":"Geocadin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11916-020-00932-1","article-title":"Posterior reversible encephalopathy syndrome","volume":"25","author":"Gewirtz","year":"2021","journal-title":"Curr. Pain Headache Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hepr.13460","article-title":"Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study","volume":"50","author":"Hatanaka","year":"2020","journal-title":"Hepatol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor","volume":"42","author":"Hussein","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000443970","article-title":"Posterior reversible encephalopathy syndrome associated with sorafenib and successful retreatment","volume":"100","author":"Laruelle","year":"2018","journal-title":"Urol. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.mehy.2014.02.022","article-title":"Posterior reversible encephalopathy syndrome: the endothelial hypotheses","volume":"82","author":"Marra","year":"2014","journal-title":"Med. Hypotheses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1079716","DOI":"10.3389\/fonc.2022.1079716","article-title":"Case report: posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer","volume":"12","author":"Matsuura","year":"2022","journal-title":"Front. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1158\/1078-0432.CCR-15-1377","article-title":"FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer","volume":"21","author":"Nair","year":"2015","journal-title":"Cancer. Clin. Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00415-015-7928-8","article-title":"Spectrum of cerebral spinal fluid findings in patients with posterior reversible encephalopathy syndrome","volume":"263","author":"Neeb","year":"2016","journal-title":"J. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40801-020-00179-7","article-title":"Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study","volume":"7","author":"Ohki","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2169\/internalmedicine.9593-17","article-title":"Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with anaplastic thyroid carcinoma","volume":"57","author":"Osawa","year":"2018","journal-title":"Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2023.0125","article-title":"Recent advances in the management of hepatocellular carcinoma","volume":"30","author":"Sankar","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1200\/JCO.2011.38.8942","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer","volume":"30","author":"Sclafani","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3390\/cancers12071867","article-title":"Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study","volume":"12","author":"Shimose","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1073274818789361","DOI":"10.1177\/1073274818789361","article-title":"Lenvatinib: a promising molecular targeted agent for multiple cancers","volume":"25","author":"Suyama","year":"2018","journal-title":"Cancer control."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/jcph.917","article-title":"Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses","volume":"57","author":"Tamai","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1136\/practneurol-2021-003194","article-title":"Posterior reversible encephalopathy syndrome (PRES): diagnosis and management","author":"Triplett","year":"2022","journal-title":"Pract. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/brainsci13010033","article-title":"Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with olfactory neuroblastoma","volume":"13","author":"Tseng","year":"2022","journal-title":"Brain Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3892\/ol.2015.4059","article-title":"Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: a case report and literature review","volume":"11","author":"Xie","year":"2016","journal-title":"Oncol. Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3350\/cmh.2022.0402","article-title":"Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective","volume":"29","author":"Xie","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11011-018-0191-9","article-title":"Multimodal MR imaging in hepatic encephalopathy: state of the art","volume":"33","author":"Zhang","year":"2018","journal-title":"Metab. Brain Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1487009\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T13:42:18Z","timestamp":1742564538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1487009\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":34,"alternative-id":["10.3389\/fphar.2025.1487009"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1487009","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1487009"}}